VRNA Verona Pharma PLC ADR

$106.91

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Verona Pharma PLC ADR

Verona Pharma plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company is headquartered in London, the United Kingdom.

Website: https://www.veronapharma.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1657312
Address
3 MORE LONDON RIVERSIDE, LONDON, GB
Valuation
Market Cap
$7.84B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
24.49
Performance
EPS
$-2.16
Dividend Yield
—
Profit Margin
0.00%
ROE
-76.40%
Technicals
50D MA
$62.52
200D MA
$41.47
52W High
$70.40
52W Low
$11.39
Fundamentals
Shares Outstanding
85M
Target Price
$81.00
Beta
0.16

VRNA EPS Estimates vs Actual

● Estimated
● Actual

VRNA News & Sentiment

Oct 07, 2025 • Zacks Commentary NEUTRAL
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases
Merck broadens its tulisokibart clinical program with three new phase IIb studies, deepening its reach across immune-mediated inflammatory diseases.
Oct 07, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.
Oct 06, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
LONDON and RALEIGH, N.C., Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Verona Pharma plc ( Nasdaq: VRNA ) ( "Verona Pharma" ) , a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD ( tradename of ...
Oct 06, 2025 • Benzinga SOMEWHAT-BULLISH
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales - Verona Pharma ( NASDAQ:VRNA )
LONDON and RALEIGH, N.C., Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Verona Pharma plc ( NASDAQ:VRNA ) ( "Verona Pharma" ) , a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD ( tradename of ...
Sep 24, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Shareholders of Verona Pharma Approve Proposed Acquisition by Merck
Transaction expected to close on October 7, 2025 Transaction expected to close on October ...
Sep 24, 2025 • Benzinga SOMEWHAT-BULLISH
Shareholders of Verona Pharma Approve Proposed Acquisition by Merck - Merck & Co ( NYSE:MRK ) , Verona Pharma ( NASDAQ:VRNA )
LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Verona Pharma plc VRNA ( "Verona Pharma" ) , a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by Merck & Co., Inc.
Sentiment Snapshot

Average Sentiment Score:

0.222
50 articles with scored sentiment

Overall Sentiment:

Bullish

VRNA Reported Earnings

Aug 06, 2025
Jun 30, 2025 (Pre market)
-0.03 Surprise
  • Reported EPS: $-0.01
  • Estimate: $0.03
  • Whisper: —
  • Surprise %: -117.2%
Apr 29, 2025
Mar 31, 2025 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.02
  • Estimate: $-0.03
  • Whisper: —
  • Surprise %: 38.5%
Feb 27, 2025
Dec 31, 2024 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.05
  • Estimate: $-0.07
  • Whisper: —
  • Surprise %: 28.6%
Nov 04, 2024
Sep 30, 2024 (Pre market)
-0.06 Surprise
  • Reported EPS: $-0.56
  • Estimate: $-0.50
  • Whisper: —
  • Surprise %: -12.0%
Aug 08, 2024
Jun 30, 2024 (Pre market)
-0.51 Surprise
  • Reported EPS: $-0.88
  • Estimate: $-0.37
  • Whisper: —
  • Surprise %: -137.8%
May 09, 2024
Mar 31, 2024 (Pre market)
-0.16 Surprise
  • Reported EPS: $-0.32
  • Estimate: $-0.16
  • Whisper: —
  • Surprise %: -100.0%
Feb 29, 2024
Dec 31, 2023 (Pre market)
0.08 Surprise
  • Reported EPS: $-0.18
  • Estimate: $-0.26
  • Whisper: —
  • Surprise %: 30.8%
Nov 02, 2023
Sep 30, 2023 (Pre market)
0.1 Surprise
  • Reported EPS: $-0.18
  • Estimate: $-0.28
  • Whisper: —
  • Surprise %: 35.7%
Aug 03, 2023
Jun 30, 2023 (Pre market)
0.21 Surprise
  • Reported EPS: $-0.08
  • Estimate: $-0.29
  • Whisper: —
  • Surprise %: 72.4%

Financials